Suraksha Diagnostic Ltd

Suraksha Diagnostic's latest results show strong revenue growth of 17.95% year-on-year, but net profit has declined by 13.06%, indicating operational challenges due to rising costs and shrinking margins. While the company remains debt-free, it needs to address these issues to sustain its growth.

As of 23-Oct, Suraksha Diagnostic Ltd's stock price is 311.85, having increased by 0.58% and showing a strong upward trend over the past week with an 8.83% total return. Despite a year-to-date decline of 16.97%, recent positive momentum and high institutional holdings indicate potential for recovery.

As of October 14, 2025, Suraksha Diagnostics is considered overvalued with a PE ratio of 45.39, a Price to Book Value of 7.08, and an EV to EBITDA of 18.26, all significantly above industry norms, while its stock has underperformed the Sensex with a year-to-date return of -22.4%.

As of October 13, 2025, Suraksha Diagnostics is fairly valued with a PE Ratio of 44.68, an EV to EBITDA of 17.97, and a ROCE of 23.40%, offering better value compared to peers like Max Healthcare and Apollo Hospitals, despite a year-to-date return of -23.63% against the Sensex's 5.36%.

As of 09-Oct, Suraksha Diagnostic Ltd is priced at 294.75, down 0.32%, and has significantly underperformed its sector and the broader market, with a year-to-date decline of 21.53%. The stock's low trading volume and negative performance trends indicate a lack of investor confidence despite healthy long-term growth indicators.

As of 24-Sep, Suraksha Diagnostic Ltd's stock price is Rs 311.25, down 1.36%, with a year-to-date decline of 17.13%. Despite strong long-term growth prospects and high institutional backing, recent performance has lagged behind the market, indicating reduced investor participation.

As of 23-Sep, Suraksha Diagnostic Ltd's stock price is at 316.70, down 0.83%, with a significant drop in delivery volume indicating reduced investor interest. Despite a strong long-term growth rate, recent performance suggests challenges in attracting investors, particularly in a slightly negative broader market context.

As of 12-Sep, Suraksha Diagnostic Ltd's stock price is 311.60, reflecting a recent upward trend with a 3.32% gain over the past week. Strong institutional backing and a low debt-to-equity ratio support its potential recovery despite a year-to-date decline.

As of 11-Sep, Suraksha Diagnostic Ltd's stock price is at 310.00, having increased by 0.49% recently, but it has declined 17.47% year-to-date. Despite strong institutional backing and recent outperformance against the Sensex, a drop in delivery volume may indicate waning investor interest.

As of 10-Sep, Suraksha Diagnostic Ltd's stock price is Rs 308.50, having increased by 0.82% recently. Despite underperforming its sector, the stock shows signs of recovery with recent gains and strong investor participation.

As of 09-Sep, Suraksha Diagnostic Ltd's stock price is at 306.00, having increased by 0.72% recently. Despite short-term gains, the stock has a year-to-date decline of 18.53%, indicating a cautious long-term outlook.

As of 08-Sep, Suraksha Diagnostic Ltd's stock price is 303.80, up 0.73% today, but down 19.12% year-to-date. Despite recent gains and strong institutional backing, the stock's performance has lagged behind the broader market.

As of 05-Sep, Suraksha Diagnostic Ltd's stock price is at 301.60, down 0.22%, and has fallen for two consecutive days, indicating bearish sentiment as it trades below all major moving averages. Despite outperforming its sector today, the stock has declined 19.70% year-to-date, with decreased investor participation and underperformance compared to the Sensex.